PROGRAM MANAGER: Stephen Clulow
OPPORTUNITY: Flexible Partnering Opportunities: Research Project, Development Project, Collaborative Development, Contract Research, Partnerships, Licensing.
Phase 1 – Review of Proposals by end November 2017
Phase 2 – Collaborations starting January 2018
Funding small proof of concept studies (€5000) to larger studies (€200000).
All financial terms are to be negotiated.
SOLUTION PROVIDER HELP DESK:
NineSigma, representing a large European pharmaceutical company, invites proposals for concepts for animal models that reflect some of the key parameters of human HFpEF and could be used to test drug substances with the potential to improve HFpEF.
Heart failure with preserved ejection fraction (HFpEF) is a form of congestive heart failure. HFpEF is characterized by abnormality in diastolic function, the filling of the heart with blood between muscle contractions. In HFpEF the left ventricle of the heart exhibits increased stiffness and a reduced ability to relax and fill with blood. As a consequence less blood enters the left ventricle and, when the ventricle contracts, the volume of blood expelled is reduced. Cardiac output is decreased and blood does not circulate efficiently. Patients with HFpEF can experience breathlessness (especially during exercise and when lying down), fatigue, swelling of the legs and feet, and increased venous blood pressure.
The frequency of HFpEF is increasing due to the increasingly aging population, and greater incidence of diabetes and obesity. There is a high medical need for effective HFpEF treatments but there are no approved medications for this condition.
Our client wants to identify drugs to treat HFpEF, but research in HFpEF lacks relevant animal models that accurately recapitulate the complexities of the human disease and can be used to test potential drug candidates.
Open to all approaches that meet the described requirements.
Submitting a response:
Appropriate responses will include only non-confidential information: